In gene therapy, immunogenicity isn't just a hurdle, it's a make-or-break factor!
Whether you are in the early or late stages of development, reliable data specific to your vector is essential to ensure relevance in your vector’s safety profile assessment.
Assessing the presence of anti-AAV antibodies and their neutralizing and toxicity capacity can also be essential. That´s where our AAV Safety Trifecta comes in!
In gene therapy, immunogenicity isn't just a hurdle, it's a make-or-break factor!
Whether you are in the early or late stages of development, reliable data specific to your vector is essential to ensure relevance in your vector’s safety profile assessment.
Assessing the presence of anti-AAV antibodies and their neutralizing and toxicity capacity can also be essential. That´s where our AAV Safety Trifecta comes in!
Our full AAV immunogenicity safety platform is built to give you a more comprehensive picture of your AAV vector, looking at it from many different angles:
No two programs are alike. That's why we offer:
Whether you're a gene therapy company, a CRO expanding your capabilities, or an academic lab exploring new serotypes, we're here to help you move forward with confidence.
Because we're more than a service provider - we're a strategic partner.
Whether you're preparing for IND submission or exploring a novel AAV construct, we're ready to support your next milestone.